Cargando…
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study
BACKGROUND AND AIMS: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity and efficacy of...
Autores principales: | Ferrante, Marc, Feagan, Brian G, Panés, Julián, Baert, Filip, Louis, Edouard, Dewit, Olivier, Kaser, Arthur, Duan, W Rachel, Pang, Yinuo, Lee, Wan-Ju, Gustafson, Dawn, Liao, Xiaomei, Wallace, Kori, Kalabic, Jasmina, D’Haens, Geert R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684487/ https://www.ncbi.nlm.nih.gov/pubmed/34077509 http://dx.doi.org/10.1093/ecco-jcc/jjab093 |
Ejemplares similares
-
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
por: Loftus, Edward V., et al.
Publicado: (2023) -
A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022) -
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019) -
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021) -
A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)